P53, Expression Of VEGF In Breast Cancer Before And After Neoadjuvant Chemotherapy And Correlation Analysis

Objective: Neoadjuvant chemotherapy in locally advanced breast cancer treatment in a wide range of applications,and its standard of care has gained widespread acceptance in clinical breast cancer patients after neoadjuvant chemotherapy embodiment pathological effectively relieve the patient's chance of survival has been significantly improvements in the treatment of breast cancer to reduce tumor stage,increase the rate of breast-conserving surgery,the elimination of systemic micrometastases has outstanding advantages and as in vivo evaluation of susceptibility testing sensitivity to chemotherapy,etc.But the large number of clinical practice has proved the existence of neoadjuvant chemotherapy in patients with chemotherapy-sensitive differences,insensitive patients,neoadjuvant chemotherapy may delay the timing of local treatment and to patients with certain side effects of chemotherapy.With the deepening of research in molecular biology,many molecular markers have been or are being used in clinical treatment of breast cancer,,prognosis and prediction of chemotherapy.In the clinical treatment of breast cancer by neoadjuvant therapy,and the patient's P53?VEGF expression meaning to explore.And its correlation analysis,which in the clinical diagnosis of breast cancer,treatment and care taken reasonable measures to control and reduce tumor size in patients with lymph node metastasis increase and enhance the patient's breast-conserving rate.Methods: By collecting before neoadjuvant hollow needle aspiration biopsy and surgical specimens after neoadjuvant chemotherapy chemotherapy,clinical treatment of breast cancer to take before and after neoadjuvant chemotherapy in patients with tumor size,axillary lymph node status,,clinical stages,P53?VEGF expression,etc.were detected by immunohistochemical streptavidin-biotin-peroxidase link method(streptavidin-peroxidase,SP method)to detect the expression of P53?VEGF,which breast cancer patients in the clinical treatment of the use of neoadjuvant chemotherapy before and after P53?VEGF expression and correlation analysis after.Inclusion criteria::according to the latest NCCN guidelines and Gallen St consensus,the indications for neoadjuvant chemotherapy for the patients with non operativelocal advanced or with breast conserving hope but due to tumor too large to protect the breast of patients;Exclusion criteria : 1 ? chemotherapy ago CNB little organization can not be completed by immunohisto-chemistry,2?Patients in the surgical biopsy has its breast tumor,chemotherapy patients and can not be implemented,3?In the course of chemotherapy cycle of chemotherapy treatment due to other reasons are not satisfied cause less than 2 weeks in patients.Due to all causes dissatisfaction case two chemotherapy cycles.The patients involved in the experiment,both locally advanced breast cancer hollow needle aspiration biopsy before chemotherapy and after chemotherapy in patients with radical surgery,chemotherapy,are in line with the conditions of admission,were female,aged 30-63 years,with a median age of 46 years,In the implementation of neoadjuvant chemotherapy prior to routine clinical examination were found to have distant metastases.Evaluation criteria: according to the relevant evaluation standard solid tumors(RECIST)its neoadjuvant chemotherapy efficacy evaluation : Complete remission: the naked eye visible tumor completely disappeared;partial remission:tumor longest diameter narrowing ?30%;stable disease : the longest diameter of tumor growth or shrink ?30% <20%;progressive disease: patients with tumors more than the maximum diameter increased ?20% ?Results: 40 patients were taken to neoadjuvant chemotherapy in patients whose clinical total effective rate was 85%,including 1 patients with clinical symptoms obtained partial remission,partial clinical symptoms of 34 patients obtained complete remission,5 patients had clinical signs of disease stable yet significant changes in two patients disease progression,the disease has not been effectively controlled,disease progression,treatment results are poor,accounting for 12.5%.The patient before and after participating in the experiment neoadjuvant chemotherapy samples collected for analysis,positive cells <5% "-",?5% for the "+",P53 tumor cell nuclei showed brown granules were positive,VEGF to tumor cytoplasm brownish yellow granules were positive,(particularly Appendix picture),Expression of their age,tumor size,VEGF,had no correlation with the lymph node metastasis,tumor grade and clinical stage were positively correlated.P53 expression with age and umor grade of patients had no correlation with the tumor size,lymph node metastasis,tumor grade werepositively correlated.Conclusion: The clinical treatment of breast cancer,VEGF exhibit overexpression in breast cancer and lymph node metastasis,tumor grade,showing a positive correlation,It means that in VEGF breast growth process played an important role,and participate in tumor cell invasion and metastasis of cancer patients.In the clinical treatment can improve the patient's lymph node metastasis,tumor grade and other indicators of VEGF expression improvement.P53 upregulated in breast cancer,and patients with tumor size,lymph node metastasis and clinical stage and other factors positively correlated.Description P53 affect early diagnosis and prognosis of breast cancer and important reason,in the clinical diagnosis and prognosis,can enhance the patient's tumor size,lymph node metastasis,tumor grade index detection and monitoring.The presence of an association between VEGF and P53,P53 for patients with high expression of anti-VEGF therapy,chemotherapy by reducing tumor growth factor-induced mutant P53,initiate apoptosis,inhibition of angiogenesis,and thus play an anti-tumor effect,which guide the comprehensive treatment of breast cancer have a certain value.P53 and future anti-VEGF therapy may become a new drug targets.